The levels of IL-6 significantly changes during radiotherapy, and is associated with the time of measurement and with the presence of prostate and radiotherapy type, IL-2 levels change during the course of radiotherapy independently of the presence of prostate, while changes in INF-ɣ depend on the presence of prostate and radiotherapy type. Here, IL2 is linked to urogenital neoplasm.